Obsidian Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies, closed aĀ $115mĀ Series B financing.
The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb. Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing. Cariad Chester, Partner, TCGX, will join Obsidian Therapeutics’ Board of Directors.
Led by Paul Wotton, Chief Executive Officer, Obsidian Therapeutics is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Its proprietary cytoDRiVEĀ® technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals.
Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.
FinSMEs
09/09/2021